Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Companies Must More Quickly Decide Development to Eliminate Drug Lag: Mr Sato
October 13, 2008
- Change Mindset from Treatment to Prevention: Dr R.H. Carmona
October 13, 2008
- NCVC to Switch Top 150 Original Drugs to Generics
October 13, 2008
- Bayer to Expand Women's Healthcare Business
October 13, 2008
- Drug Lag Attributable to Delay in Starting Clinical Trials: OPIR Study
October 13, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
- Original and Generic Amlodipine Products Show Same Effects
October 13, 2008
- Kyowa Hakko Kirin Sets Out Aiming at Becoming Global Specialty Pharma
October 13, 2008
- GENERICS NEWS IN BRIEF
October 13, 2008
- SELF-MEDICATION NEWS IN BRIEF
October 13, 2008
- RAD001 Prolongs PFS in Patients with RCC: Novartis
October 13, 2008
- ActHIB to Reach Japanese Market in December?
October 13, 2008
- Lantus + Apidra Combination Therapy Effective for Diabetics
October 13, 2008
- Sales Force Effectiveness Japan 2008 Conference: eyeforpharma
October 13, 2008
- R&D NEWS IN BRIEF
October 13, 2008
- Kowa Trains Managers on How to Coach MRs during Customer Visits
October 13, 2008
- 16th JBCS Annual Meeting
October 13, 2008
- Biosimilars Should Reduce Healthcare Costs to Be Generally Accepted
October 13, 2008
- DDS Development Key to AMD
October 13, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…